Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00654433 · ClinicalTrials.gov registry record · Phase 3
ALD-101 Adjuvant Therapy of Unrelated Umbilical Cord Blood Transfusion (UCBT) in Patients With Inherited Metabolic Diseases
A Phase 3 study, sponsored by Aldagen.
- Terminated
- Registry status
- Phase 3
- Development phase
- 40
- Enrollment target
NCT00654433: Clinical Trial Phase 3 study, sponsored by Aldagen.
NCT00654433 is a Phase 3 study that was terminated before completion, run by Aldagen. The registered enrollment target is 40 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00654433, a Phase 3 study, was terminated before completion, sponsored by Aldagen.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 40 participants
- Enrollment target
Study Summary
Eligible research subjects will receive an unrelated umbilical cord blood transfusion as a possible cure for their inherited metabolic disease. A portion of cord blood cells (ALD-101) will be separated from the cord blood unit and given approximately 4 hours after the standard cord blood transfusion. The study will test if the supplemental cells will increase the speed at which normal levels of circulating blood cells are re-established after transplant.
Interventions
- BIOLOGICAL ALD-101
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2008-03 |
| Est. Completion | 2011-11 |
| Phase | Phase 3 |
Why NCT00654433 stopped before completion
NCT00654433 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 1 intervention - of which ALD-101 is the first listed.
NCT00654433 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00654433 about?
NCT00654433 is a clinical study titled "ALD-101 Adjuvant Therapy of Unrelated Umbilical Cord Blood Transfusion (UCBT) in Patients With Inherited Metabolic Diseases". Eligible research subjects will receive an unrelated umbilical cord blood transfusion as a possible cure for their inherited metabolic disease. A portion of cord blood cells (ALD-101) will be separated from the cord blood unit and given approximately 4 hours after the standard cord blood transfusion...
What is the current status of trial NCT00654433?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 40 participants. The study started on 2008-03. Estimated completion is 2011-11.
What interventions are being tested in trial NCT00654433?
The interventions under investigation include: ALD-101 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00654433?
This trial is sponsored by Aldagen, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00654433's enrollment target sits among peer trials
40 1878th of 2000 higher than 103 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia